GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Revive Therapeutics Ltd (FRA:31R) » Definitions » Cash Ratio

Revive Therapeutics (FRA:31R) Cash Ratio : 0.00 (As of Dec. 2023)


View and export this data going back to 2017. Start your Free Trial

What is Revive Therapeutics Cash Ratio?

The Cash Ratio measures a company’s ability to meet its short-term obligations with cash and near-cash resources. It is calculated as a company's Cash, Cash Equivalents, Marketable Securities divides by its Total Current Liabilities. Revive Therapeutics's Cash Ratio for the quarter that ended in Dec. 2023 was 0.00.

Revive Therapeutics has a Cash Ratio of 0.00. It indicates that there are more current liabilities than Cash, Cash Equivalents, Marketable Securities, and the company does not have sufficient cash on hand to pay off its short-term debt.

The historical rank and industry rank for Revive Therapeutics's Cash Ratio or its related term are showing as below:

FRA:31R' s Cash Ratio Range Over the Past 10 Years
Min: 0.12   Med: 3.97   Max: 41.33
Current: 0.22

During the past 10 years, Revive Therapeutics's highest Cash Ratio was 41.33. The lowest was 0.12. And the median was 3.97.

FRA:31R's Cash Ratio is ranked worse than
71.32% of 1025 companies
in the Drug Manufacturers industry
Industry Median: 0.57 vs FRA:31R: 0.22

Revive Therapeutics Cash Ratio Historical Data

The historical data trend for Revive Therapeutics's Cash Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Revive Therapeutics Cash Ratio Chart

Revive Therapeutics Annual Data
Trend Jun14 Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
Cash Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.48 3.98 27.77 0.94 0.61

Revive Therapeutics Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Jun23 Sep23 Dec23
Cash Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Revive Therapeutics's Cash Ratio

For the Drug Manufacturers - Specialty & Generic subindustry, Revive Therapeutics's Cash Ratio, along with its competitors' market caps and Cash Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Revive Therapeutics's Cash Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Revive Therapeutics's Cash Ratio distribution charts can be found below:

* The bar in red indicates where Revive Therapeutics's Cash Ratio falls into.



Revive Therapeutics Cash Ratio Calculation

The Cash Ratio measures a company's ability to meet its short-term obligations with its cash and near-cash resources.

Revive Therapeutics's Cash Ratio for the fiscal year that ended in Jun. 2023 is calculated as:

Cash Ratio (A: Jun. 2023 )=Cash, Cash Equivalents, Marketable Securities/Total Current Liabilities
=1.45/2.387
=0.61

Revive Therapeutics's Cash Ratio for the quarter that ended in Dec. 2023 is calculated as:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Revive Therapeutics  (FRA:31R) Cash Ratio Explanation

The cash ratio is more conservative than other liquidity ratios, such as Quick Ratio and Current Ratio, because it only considers a company's most liquid resources. The numerator of cash ratio only considers Cash, Cash Equivalents and marketable securities. Other current assets, such as accounts receivable and inventories, are not included. The rationale is that these assets may require time to be transformed into cash, and the amount of money received is also uncertain.

The cash ratio shows a company’s ability to pay all current liabilities immediately without selling or liquidating other assets. Generally speaking, a higher cash ratio suggests the company has a stronger ability to cover its short-term debt. However, a high cash ratio could also indicate inefficient management: the company is inefficient in making full utilization of cash to invest protential profitable project. It may also suggest that the company is not confident about future profitability.

In general, the higher the cash ratio, the better the company's liquidity position.


Revive Therapeutics Cash Ratio Related Terms

Thank you for viewing the detailed overview of Revive Therapeutics's Cash Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Revive Therapeutics (FRA:31R) Business Description

Traded in Other Exchanges
Address
82 Richmond Street East, Toronto, ON, CAN, M5C 1P1
Revive Therapeutics Ltd is focused on the research, development, and commercialization of novel psychedelic and cannabinoid-based life sciences products and drug repurposing for infectious diseases. The firm's technology is being developed to fill the medical needs for diseases and disorders such as pain, inflammation, and wound care.

Revive Therapeutics (FRA:31R) Headlines

No Headlines